Xcout Intel
Omnix Medical
Omnix Medical is a biopharmaceutical company that develops novel antibiotic agents and antimicrobial peptides to treat infections caused by drug-resistant bacteria. The company focuses on creating first-in-its-class anti-infective therapeutics, such as its lead compound OMN6, to target life-threatening bacterial strains.
Subscribe to see Omnix Medical’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Omnix Medical at a glance
Omnix Medical is a biotech company headquartered in Israel, founded in 2015. Its most recent funding round raised $11.7M in January 2021.
Omnix Medical funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $11.7M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Omnix Medical competitors
A few of Omnix Medical's closest competitors — see the full list of competitors and alternatives →
Bugworks Research Inc. is a clinical-stage biopharmaceutical company headquartered in Bangalore, India, developing novel therapeutics to combat antimicrobial resistance.
BioVersys AG is an award-winning, privately-owned Swiss pharmaceutical and biotech company headquartered in Basel, Switzerland, focused on the research and development of antibacterial treatments for drug-resistant bacterial infections.
Maxwell Biosciences, Inc. is a biotechnology company based in Austin, Texas. It develops biomimetic, peptide-inspired anti-infective drugs designed to act as a synthetic immune system.
Qpex Biopharma, Inc. is a biopharmaceutical company located in San Diego, California, specializing in infectious disease solutions as part of the Shionogi Group.
TXN Systems AB is a healthcare company developing an innovative antibiotic regimen targeted at treating complicated urinary tract infections caused by antibiotic-resistant bacteria.
AMR Bio is a clinical-stage biotechnology company headquartered in London, United Kingdom, focused on infection prevention and antimicrobial resistance. The company is dedicated to developing novel anti-infectives, including its Phase 3-ready, first-in-class topical antimicrobial candidate XF-73.
Get Omnix Medical's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Omnix Medical in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access